De novo ARID1A Coffin-Siris syndrome with hypothyroidism and dyslipidemia: A case report and literature review
World Journal of Clinical Cases · 06.07.2026 · 14 (19)
DOI: 10.12998/wjcc.120716 ↗Kurz gefasst
Fallbericht in der Zeitschrift World Journal of Clinical Cases, online erschienen am 06.07.2026. Verfasst von Michael N Fragos und 8 weiteren Autor:innen. Die Arbeit nennt 66 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND Coffin-Siris syndrome (CSS) is a rare BRG1/BRM-associated factor (BAF) - SWI/SNF (SWItch/Sucrose non-fermentable) - related neurodevelopmental disorder. Endocrine manifestations primarily involve growth disturbances, whereas thyroid dysfunction and dyslipidemia are not considered recurrent syndromic features. CASE SUMMARY A 4-year and 4-month-old boy with typical CSS features (coarse facies with long eyelashes, fifth-digit distal phalanx/nail hypoplasia/aplasia, dorsal hypertrichosis, developmental delay/intellectual disability) and short stature developed subclinical hypothyroidism at the age of 4 years and 2 months old, while also exhibiting hypercholesterolemia. Whole-exome sequencing identified a pathogenic ARID1A variant (c.4102-1G>A) consistent with CSS and a heterozygous likely pathogenic LDLR variant (c.251C>T), consistent with familial hypercholesterolemia. Levothyroxine treatment achieved biochemical euthyroidism, and along with lifestyle interventions, was followed by transient improvement in growth velocity. Dyslipidemia was managed conservatively. Subsequent decline in growth velocity and low insulin-like growth factor 1 concentrations prompted growth hormone (GH) stimulation testing, which proved to be pathological. Consideration of recombinant GH therapy raised concerns due to the reported increased hepatoblastoma risk in ARID1A -related CSS and insufficient clinical evidence and recommendations. CONCLUSION Although not typical for CSS, this proband highlights that thyroid and lipid abnormalities may coexist, and supports selective thyroid-stimulating hormone/free T4 (thyroxine) and lipid screening in CSS when clinically indicated, while attributing hypercholesterolemia primarily to LDLR -mediated familial hypercholesterolemia. Individualized endocrine surveillance and follow-up are essential for the optimal management of CSS in children.
Zitieren
APA
Fragos, M. N., Toulia, I., Grammatikopoulou, M. G., Savvidou, P., Taiganidis, I., Zissiadis, P., Antachopoulos, C., Goulis, D. G., & Tsiroukidou, K. (2026). De novo ARID1A Coffin-Siris syndrome with hypothyroidism and dyslipidemia: A case report and literature review. World Journal of Clinical Cases, 14(19). https://doi.org/10.12998/wjcc.120716
Vancouver
Fragos MN, Toulia I, Grammatikopoulou MG, Savvidou P, Taiganidis I, Zissiadis P, et al. De novo ARID1A Coffin-Siris syndrome with hypothyroidism and dyslipidemia: A case report and literature review. World Journal of Clinical Cases. 2026;14(19). doi:10.12998/wjcc.120716
BibTeX
@article{Fragos2026,
author = {Fragos, Michael N and Toulia, Ilektra and Grammatikopoulou, Maria G and Savvidou, Parthena and Taiganidis, Ioannis and Zissiadis, Panagiota and Antachopoulos, Charalampos and Goulis, Dimitrios G and Tsiroukidou, Kyriaki},
title = {De novo ARID1A Coffin-Siris syndrome with hypothyroidism and dyslipidemia: A case report and literature review},
journal = {World Journal of Clinical Cases},
year = {2026},
volume = {14},
number = {19},
doi = {10.12998/wjcc.120716}
}
EUVIMED